Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $52.2 million.

  • Rocket Pharmaceuticals' Operating Expenses fell 2474.22% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.5 million, marking a year-over-year decrease of 851.46%. This contributed to the annual value of $273.2 million for FY2024, which is 521.68% up from last year.
  • Rocket Pharmaceuticals' Operating Expenses amounted to $52.2 million in Q3 2025, which was down 2474.22% from $71.1 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Operating Expenses' 5-year high stood at $73.7 million during Q2 2024, with a 5-year trough of $34.0 million in Q2 2021.
  • Moreover, its 5-year median value for Operating Expenses was $62.7 million (2024), whereas its average is $58.5 million.
  • Data for Rocket Pharmaceuticals' Operating Expenses shows a peak YoY increase of 8127.58% (in 2021) and a maximum YoY decrease of 2516.0% (in 2021) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Operating Expenses (Quarter) stood at $44.3 million in 2021, then soared by 55.83% to $69.1 million in 2022, then fell by 8.4% to $63.3 million in 2023, then fell by 0.92% to $62.7 million in 2024, then decreased by 16.66% to $52.2 million in 2025.
  • Its last three reported values are $52.2 million in Q3 2025, $71.1 million for Q2 2025, and $64.4 million during Q1 2025.